Moderna Shares Recover After Decline Following Cancer Vaccine Success
Moderna (NASDAQ:MRNA) shares experienced a 2.9% increase in pre-market trading, marking a recovery after several sessions of decline. This decline followed a notable rally sparked by encouraging Phase 3 trial results for its personalized mRNA cancer vaccine, intismeran autogene. The trial demonstrated a significant reduction in melanoma recurrence among patients whose tumors had been surgically removed, representing a milestone as the first successful late-stage trial for an mRNA-based cancer vaccine.
The initial excitement surrounding the trial results led to a sharp increase in Moderna's stock price, but recent profit-taking has tempered this rally. Investors are now reassessing the commercial potential and associated risks of the treatment in light of the initial enthusiasm.
For Your Trading Desk
Sponsor Spike Success.
Analyst commentary has provided additional support for Moderna's stock ahead of the market's opening. Barclays analyst Eliana Merle raised the price target for Moderna to $125 from $48 while maintaining an Equal Weight rating. This significant increase in the target price reflects the positive Phase 3 results for intismeran.
Wolfe Research also upgraded Moderna from Underperform to Peerperform following the trial data, estimating potential unadjusted peak sales of $9.2 billion across four indications: adjuvant melanoma, renal cell carcinoma (RCC), muscle-invasive bladder cancer (MIBC), and non-small cell lung cancer (NSCLC), not accounting for Moderna's profit-sharing arrangement with Merck.
Despite these favorable assessments, investors remain cautious as they evaluate the commercial prospects of intismeran and whether the vaccine can convert its clinical success into substantial revenue.
The recent rebound in Moderna's shares comes after a remarkable year, with the stock gaining approximately 392% year to date following the successful Phase 3 melanoma trial. This surge has been accompanied by significant volatility, as the initial positive response to the trial results was followed by profit-taking and weakness in parts of the biotechnology sector.
Merck, Moderna's partner in the development of intismeran, has also seen benefits from the optimism surrounding the program. Investors across the biotechnology sector are reassessing the implications of the first positive Phase 3 result for an mRNA cancer vaccine.
The broader market conditions on Tuesday were also favorable, with the Nasdaq Composite rising by 1.0% and the S&P 500 gaining 0.5%, creating a supportive environment for higher-risk biotechnology stocks.
The combination of a stronger market, the significant price target increase from Barclays, and the stabilization following Moderna's recent correction contributed to the stock's rise in pre-market trading. Attention is now focused on the potential commercial pathway for intismeran, with analysts suggesting that 2027 could be a target year for commercialization if the program continues to yield positive data and navigates the necessary regulatory processes.
This long-term opportunity continues to attract interest in Moderna, although the stock remains below its 52-week high of $176.66 after a period of notable volatility.




